NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
African Discovery Group announces signing of Definitive Sales and Purchase Agreement for Butembo Copper Asset in the Democratic Republic of Congo; name change to Copper Intelligence, Inc
Blackrock Silver to Present at the Precious Metals and Critical Minerals Virtual Investor Conference on February 10th 2026
Saga Metals Acknowledges U.S. Strategic Critical Minerals Reserve "Project Vault" and Highlights Titanium's Strategic Importance to North American Defense Supply Chains
